Pfizer Inc (PFE)

PFE (NYSE:Drugs) EQUITY
$33.36
neg -0.02
-0.06%
Today's Range: 33.26 - 33.49 | PFE Avg Daily Volume: 18,739,900
Last Update: 08/16/17 - 4:00 PM EDT
Volume: 10,557,566
YTD Performance: 2.77%
Open: $33.33
Previous Close: $33.38
52 Week Range: $29.83 - $35.38
Oustanding Shares: 5,947,349,054
Market Cap: 198,106,196,989
6-Month Chart
TheStreet Ratings Grade for PFE
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 6 6 7
Moderate Buy 0 0 0 0
Hold 7 7 7 8
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2.20 2.29 2.29 2.25
Latest Dividend: 0.32
Latest Dividend Yield: 3.84%
Dividend Ex-Date: 08/02/17
Price Earnings Ratio: 24.31
Price Earnings Comparisons:
PFE Sector Avg. S&P 500
24.31 24.30 36.20
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
0.78% -4.93% 16.55%
GROWTH 12 Mo 3 Yr CAGR
Revenue 8.10 0.00 0.01
Net Income 3.70 -0.40 -0.14
EPS 5.40 -0.60 -0.28
Earnings for PFE:
EBITDA 19.49B
Revenue 52.82B
Average Earnings Estimates
Qtr (09/17) Qtr (12/17) FY (12/17) FY (12/18)
Average Estimate $0.63 $0.56 $2.56 $2.74
Number of Analysts 6 6 9 9
High Estimate $0.67 $0.59 $2.58 $2.83
Low Estimate $0.60 $0.53 $2.54 $2.64
Prior Year $0.61 $0.47 $2.40 $2.56
Growth Rate (Year over Year) 3.83% 20.21% 6.67% 6.99%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
RMPIA
By

Jim Collins

 | Aug 3, 2017 | 5:05 PM EDT
The blue-chip index gets all the attention, but doesn't necessarily deserve it.

bullishBMO Capital Upgrades Pfizer to Outperform

Aug 2, 2017 | 9:00 AM EDT
Pfizer was upgraded at BMO Capital to "Outperform" from "Market Perform" with a $37 price target.
By

Jim Cramer

 | Aug 1, 2017 | 1:48 PM EDT
Jim Cramer weighs in on Tuesday's trending stocks.
RMPIA
By

Jim Cramer

 | Aug 1, 2017 | 11:34 AM EDT
They haven't distinguished themselves.
By

Skip Raschke

 | Jul 31, 2017 | 8:30 AM EDT
If you like pharma, now is the time to scale into the sector.

bearishCredit Suisse Cuts Pfizer to Neutral

Jul 20, 2017 | 8:55 AM EDT
Pfizer was downgraded at Credit Suisse to "Neutral" from "Outperform" with a $36 price target.
RMPIA
By

Alex Frew McMillan

 | Jun 27, 2017 | 9:00 AM EDT
The days of rapid growth are far behind Japan. So can these Tokyo listings deliver as much bite as the FANGs?
By

Skip Raschke

 | Jun 8, 2017 | 9:03 AM EDT
This tactic for PFE is a rare setup for those bullish in any underlying stock.
RMPIA
By

Jim Cramer

 | Jun 7, 2017 | 7:29 AM EDT
The handwringers will be out in full force. Their fear creates buying opportunities.
By

James "Rev Shark" DePorre

 | May 31, 2017 | 12:55 PM EDT
Keep in mind that downside is not going to come too easily.
we like this chart here, it appears ready to move higher. BOUGHT BZUN OCT 35 CALL AT 3....
Large-cap, high-quality McKesson (MCK) is too cheap now, at $147.51 or so. The stock hit $...
Hug declines in Advance Auto Parts (AAP) and Dick's Sporting Goods (DKS) made for great ch...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.